| 1 |
35159907 | Biomimetic Citrate-Coated Luminescent Apatite Nanoplatforms for Diclofenac Delivery in Inflammatory Environments. | 2022 Feb 6 |
3 |
| 2 |
35585779 | Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. | 2022 May 18 |
1 |
| 3 |
33813964 | Non-ulcerogenic pyrazolyl 2-hydroxychalcones and pyrazolylpyrazolines derived from naturally existing furochromone (khellin): semi-synthesis, docking study and anti-inflammatory activity. | 2021 Apr 5 |
1 |
| 4 |
33964802 | New nitric oxide-releasing indomethacin derivatives with 1,3-thiazolidine-4-one scaffold: Design, synthesis, in silico and in vitro studies. | 2021 Jul |
2 |
| 5 |
34182020 | Recategorization of Non-Aspirin Nonsteroidal Anti-inflammatory Drugs According to Clinical Relevance: Abandoning the Traditional NSAID Terminology. | 2021 Nov |
1 |
| 6 |
34568119 | Safe and appropriate use of diclofenac in chronic kidney disease: An Indian perspective. | 2021 Jul |
1 |
| 7 |
31878864 | Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-Methanones as a Novel Inflammation Medication. | 2020 |
1 |
| 8 |
31916080 | Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. | 2020 Apr |
1 |
| 9 |
31985369 | Inhibition of Cyclooxygenase Enzyme by Bioflavonoids in Horsegram Seeds Alleviates Pain and Inflammation. | 2020 |
1 |
| 10 |
28179185 | The use of diclofenac sodium in urological practice: A structural and neurochemical based review. | 2018 Jan |
4 |
| 11 |
28870762 | Peripheral nerve and diclofenac sodium: Molecular and clinical approaches. | 2018 Jan |
2 |
| 12 |
29235601 | Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines. | 2018 Jan 2 |
2 |
| 13 |
29238904 | Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. | 2018 Aug |
1 |
| 14 |
30083389 | Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations. | 2018 |
1 |
| 15 |
26823679 | Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. | 2016 |
1 |
| 16 |
27014880 | Spinal antinflammatory action of Diclofenac. | 2016 Jun |
1 |
| 17 |
27548780 | Cyclic Dipeptide Shuttles as a Novel Skin Penetration Enhancement Approach: Preliminary Evaluation with Diclofenac. | 2016 |
1 |
| 18 |
27687548 | NSAIDs diclofenac, indomethacin, and meloxicam highly upregulate expression of ICAM-1 and COX-2 induced by X-irradiation in human endothelial cells. | 2016 Oct 28 |
3 |
| 19 |
27831630 | Safety and efficacy of low doses of diclofenac on acute pain in the emergency setting. | 2016 Oct |
2 |
| 20 |
24796327 | Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. | 2014 |
1 |
| 21 |
25378670 | Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality. | 2014 Nov 25 |
2 |
| 22 |
23289871 | Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. | 2013 Jan 5 |
7 |
| 23 |
20817448 | Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry. | 2011 Jan 5 |
1 |
| 24 |
21830840 | Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. | 2011 Sep 1 |
1 |
| 25 |
22091869 | Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR. | 2011 Dec 22 |
3 |
| 26 |
19841157 | Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. | 2010 Jan |
2 |
| 27 |
20092437 | A Review on the risk of myocardial infarction associated with the NSAID diclofenac. | 2010 Mar |
3 |
| 28 |
20237495 | Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. | 2010 Aug |
1 |
| 29 |
20470236 | Diclofenac: an update on its mechanism of action and safety profile. | 2010 Jul |
1 |
| 30 |
20631416 | Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. | 2010 May-Jun |
1 |
| 31 |
20648923 | In vitro anti-proliferative effects of the willow bark extract STW 33-I. | 2010 |
1 |
| 32 |
21056807 | Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. | 2010 Nov |
1 |
| 33 |
19602986 | Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. | 2009 Aug |
1 |
| 34 |
20096163 | Field treatment of actinic keratoses - focus on COX-2-inhibitors. | 2009 Dec |
1 |
| 35 |
18434566 | Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. | 2008 Jun |
1 |
| 36 |
18674517 | Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo. | 2008 Sep 15 |
1 |
| 37 |
17164136 | Pharmacodynamic of cyclooxygenase inhibitors in humans. | 2007 Jan |
3 |
| 38 |
17965743 | Antagonism of thromboxane receptors by diclofenac and lumiracoxib. | 2007 Dec |
1 |
| 39 |
18605234 | Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats. | 2007 |
1 |
| 40 |
16934053 | The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. | 2006 Sep |
1 |
| 41 |
15133778 | Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. | 2004 May |
1 |
| 42 |
15555544 | Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1). | 2004 Dec 24 |
1 |
| 43 |
12534640 | Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. | 2003 Jan |
1 |
| 44 |
12852704 | Valdecoxib: a review. | 2003 Mar |
1 |
| 45 |
12966366 | Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. | 2003 Sep |
3 |
| 46 |
14655004 | [Clinical pharmacology of the selective COX-2 inhibitors]. | 2003 Dec |
1 |
| 47 |
11874389 | Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. | 2002 Mar |
3 |
| 48 |
11556519 | In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. | 2001 Aug |
1 |
| 49 |
11742186 | Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs. | 2001 Dec |
1 |
| 50 |
11028250 | Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. | 2000 Oct |
1 |